Repligen Q1 revenue $169M (+10% YoY); adjusted EPS $0.39 vs $0.30; orders up high-teens

REPLIGEN CORP

2025-Q1 EPS reported $0.10 revenue$169,172,000

Revenue $169M, up 10% reported, 14% organic non-COVID YoY; GAAP EPS $0.10, adjusted EPS $0.39.
Adjusted operating income $23M, up 72% YoY; adjusted gross margin 53.7% vs 49.2%.
Orders grew high-teens YoY with all four franchises up double-digits; biopharma and consumables record ex-COVID.
FY2025 guidance reiterated: organic growth 9.5%-13.5%; adjusted EPS $1.63-$1.72.
Closed acquisition of 908 Devices' bioprocessing portfolio; minimal tariff impact expected.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.